DJIA 17,798.49 -14.90 -0.08%
NASDAQ 5,127.53 11.38 0.22%
S&P 500 2,090.11 1.24 0.06%
market minute promo

67.85 -0.23 (-0.34%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

BMY $67.85 -0.34%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $68.08
Previous Close $68.08
Daily Range $67.81 - $68.44
52-Week Range $51.82 - $70.54
Market Cap $113.2B
P/E Ratio 64.23
Dividend (Yield) $1.48 (2.2%)
Ex-Dividend Date
Dividend Pay Date
Volume 1,385,063
Average Daily Volume 5,700,409
Current FY EPS $1.89




Drug Makers

Bristol-Myers Squibb Co. (BMY) Description

Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments. Website:

News & Commentary Rss Feed

Why Aduro Biotech Is Crashing Today

A set back for a promising new therapy for pancreatic cancer is weighing on shares.

FDA declines expanded approval for Bristol-Myers' Opdivo drug

Bristol-Myers' Opdivo Gets FDA Nod for Another Indication

Clinton's Price Caps Are A Non-Starter: Liana Moussatos Of Wedbush Securities

Premarket Biotech Digest: CTI BioPharma Undervalued, Shire's New Bid, BioMarin's DMD Drug Review

Bristol-Myers' Opdivo Label Now Includes Renal Cell Cancer

FDA approves expanded use of Bristol-Myers' skin cancer drug

Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as

Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma

5 Dividend Stocks to Buy in November

These five companies can provide years of steady payouts for patient investors.

FDA approves Bristol's Opdivo for kidney cancer

See More BMY News...

BMY's Top Competitors

BMY $67.85 (-0.34%)
Current stock: BMY
JNJ $102.37 (0.40%)
Current stock: JNJ
PFE $32.79 (-0.24%)
Current stock: PFE
RHHBY $33.50 (0.93%)
Current stock: RHHBY